Vanda Pharmaceuticals Overview
- Year Founded
-
2002
- Status
-
Public
- Employees
-
533
- Stock Symbol
-
VNDA
- Investments
-
2
- Share Price
-
$3.44
- (As of Friday Closing)
Vanda Pharmaceuticals General Information
Description
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Contact Information
Website
www.vandapharma.comCorporate Office
- 2200 Pennsylvania Avenue Northwest
- Suite 300E
- Washington, DC 20037
- United States
Corporate Office
- 2200 Pennsylvania Avenue Northwest
- Suite 300E
- Washington, DC 20037
- United States
Vanda Pharmaceuticals Stock Performance
As of 20-Nov-2026, Vanda Pharmaceuticals’s stock price is $3.44. Its current market cap is $208M with 60.5M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.44 | $3.67 | $3.42 - $9.94 | $208M | 60.5M | 1.05M | -$4.62 |
Vanda Pharmaceuticals Financials Summary
As of 30-Sep-2026, Vanda Pharmaceuticals has a trailing 12-month revenue of $229M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 149,675 | 238,395 | (89,025) | (237,227) |
| Revenue | 229,278 | 216,105 | 198,772 | 192,640 |
| EBITDA | (157,235) | (126,730) | (13,122) | 10,673 |
| Net Income | (274,829) | (220,474) | (18,900) | 2,509 |
| Total Assets | 382,327 | 488,948 | 656,204 | 648,440 |
| Total Debt | 21,971 | 12,622 | 12,360 | 9,404 |
Vanda Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Vanda Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Vanda Pharmaceuticals Comparisons
Industry
Financing
Details
Vanda Pharmaceuticals Competitors (45)
One of Vanda Pharmaceuticals’s 45 competitors is Novartis, a Corporation company based in Basel, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Novartis | Corporation | Basel, Switzerland | ||||
| Cipla | Corporation | Mumbai, India | ||||
| Evonile Pharma | Private Equity-Backed | Mumbai, India | ||||
| Sanofi | Corporation | Gentilly, France | ||||
| Merck & Co. | Corporation | Rahway, NJ |
Vanda Pharmaceuticals Patents
Vanda Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026174219-A1 | Method of treatment of hypertension with iloperidone | Pending | 13-Feb-2025 | ||
| WO-2026156184-A1 | Method of treatment with milsaperidone | Pending | 17-Jan-2025 | ||
| WO-2026152024-A1 | Method of treating nausea and vomiting after glp-1r agonist administration | Pending | 09-Jan-2025 | ||
| US-20250375409-A1 | Treatment of rem behavior disorder | Pending | 11-Jun-2024 | ||
| AU-2025224045-A1 | Treatment of dry eye disease | Pending | 22-Feb-2024 | A61K31/53 |
Vanda Pharmaceuticals Signals
Vanda Pharmaceuticals Investments (2)
Vanda Pharmaceuticals’s most recent deal was a Corporate Asset Purchase with AnaptysBio (Rights to Imsidolimab). The deal was made on 26-Feb-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| AnaptysBio (Rights to Imsidolimab) | 26-Feb-2026 | Corporate Asset Purchase | Buildings and Property | ||
| Actelion Pharmaceuticals (United States and Canadian Rights to Ponvory) | 07-Dec-2023 | Corporate Asset Purchase | Buildings and Property |
Vanda Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
32.3 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Vanda Pharmaceuticals FAQs
-
When was Vanda Pharmaceuticals founded?
Vanda Pharmaceuticals was founded in 2002.
-
Where is Vanda Pharmaceuticals headquartered?
Vanda Pharmaceuticals is headquartered in Washington, DC.
-
What is the size of Vanda Pharmaceuticals?
Vanda Pharmaceuticals has 533 total employees.
-
What industry is Vanda Pharmaceuticals in?
Vanda Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Vanda Pharmaceuticals a private or public company?
Vanda Pharmaceuticals is a Public company.
-
What is Vanda Pharmaceuticals’s stock symbol?
The ticker symbol for Vanda Pharmaceuticals is VNDA.
-
What is the current stock price of Vanda Pharmaceuticals?
As of 20-Nov-2026 the stock price of Vanda Pharmaceuticals is $3.44.
-
What is the current market cap of Vanda Pharmaceuticals?
The current market capitalization of Vanda Pharmaceuticals is $208M.
-
What is Vanda Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Vanda Pharmaceuticals is $229M.
-
Who are Vanda Pharmaceuticals’s competitors?
Novartis, Cipla, Evonile Pharma, Sanofi, and Merck & Co. are some of the 45 competitors of Vanda Pharmaceuticals.
-
What is Vanda Pharmaceuticals’s annual earnings per share (EPS)?
Vanda Pharmaceuticals’s EPS for 12 months was -$4.62.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process